TABLE 1.
Demography and baseline characteristics (Full analysis set)
| Placebo (N = 75) | Imeglimin 500 mg (N = 75) | Imeglimin 1000 mg (N = 73) | Imeglimin 1500 mg (N = 73) | |
|---|---|---|---|---|
| Gender | ||||
| Men, n (%) | 49 (65%) | 49 (65%) | 48 (66%) | 52 (71%) |
| Women, n (%) | 26 (35%) | 26 (35%) | 25 (34%) | 21 (29%) |
| Age (y), mean (SD) | 60.2 (9.5) | 58.7 (8.5) | 59.9 (10.0) | 57.6 (10.8) |
| Body weight (kg), mean (SD) | 70.4 (14.8) | 68.5 (15.2) | 67.6 (12.5) | 73.3 (15.6) |
| BMI (kg/m2), mean (SD) | 25.8 (4.5) | 25.2 (4.6) | 25.2 (3.9) | 26.8 (4.4) |
| Waist circumference (cm), mean (SD) | 90.9 (11.2) | 89.3 (11.2) | 89.0 (9.9) | 92.8 (11.1) |
| Diabetes duration (y), mean (SD) | 6.26 (6.3) | 7.2 (6.3) | 6.25 (5.5) | 5.28 (5.2) |
| Patients with previous diabetes treatment, n(%) | 46 (61.3%) | 44 (58.7%) | 47 (64.4%) | 45 (61.6%) |
|
4 (5.3%) | 1 (1.3%) | 5 (6.8%) | 0 |
|
20 (26.7%) | 22 (29.3%) | 26 (35.6%) | 27 (37.0%) |
|
1 (1.3%) | 0 | 1 (1.4%) | 0 |
|
11 (14.7%) | 8 (10.7%) | 7 (9.6%) | 6 (8.2%) |
|
7 (9.3%) | 6 (8.0%) | 4 (5.5%) | 8 (11%) |
|
3 (4.0%) | 3 (4.0%) | 3 (4.1%) | 2 (2.7%) |
|
0 | 4 (5.3%) | 1 (1.4%) | 2 (2.7%) |
| eGFR (mL/min), mean (SD) | 73.4 (13.1) | 73.8 (12.6) | 75.1 (12) | 75.2 (15.2) |
Abbreviations: AGI, alpha glucosidase inhibitor; BMI, body mass index; DPP4‐I, dipeptidyl peptidase‐4 inhibitor; GLIN, glinide; SD, standard deviation; SGLT2‐I, sodium‐glucose co‐transporter‐2 inhibitor; SU, sulphonylurea; TZD, thiazolidinedione.